Oracle Introduces Oracle Health Sciences Data Management Workbench
Bi-directional Integration with Oracle Health Sciences InForm Enables Real-time Clinical Trial Data Visibility and Reduces Data Management Costs
Oracle announced the release of the Oracle Health Sciences Data Management Workbench. The tool aims to allow researchers to "integrate, reconcile, and analyze clinical data faster and more accurately," automating the data load, transform and cleanse processes.
The solution integrates with Oracle Life Sciences Data Hub to automatically aggregate, integrate, and recincile the volume of trial data. By increasing data integration and standardizing data formats throughout the study process, Oracle Health Sciences Data Management Workbench also automates the identification and correction of discrepancies in multi-source data that can jeopardize the validity of a study. Oracle Health Sciences Data Management Workbench also integrates with Oracle Health Sciences InForm to enable automated, bi-directional and real-time information flow between the systems.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
